Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
TG Therapeutics, Inc. - Common Stock
(NQ:
TGTX
)
29.03
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Mar 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about TG Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
TG Therapeutics Inc (NASDAQ:TGTX) Reports Mixed Q2 2025 Results, Raises Full-Year BRIUMVI Revenue Guidance
↗
August 04, 2025
TG Therapeutics reported mixed Q2 2025 results, missing revenue and EPS estimates but raising full-year BRIUMVI sales guidance. Shares dipped slightly as investors weighed the outlook.
Via
Chartmill
Earnings Scheduled For August 4, 2025
↗
August 04, 2025
Via
Benzinga
What's Next: TG Therapeutics's Earnings Preview
↗
August 01, 2025
Via
Benzinga
TG THERAPEUTICS INC (NASDAQ:TGTX) – A High Growth Momentum Stock with Strong Technical Setup
↗
July 17, 2025
TG THERAPEUTICS INC (NASDAQ:TGTX) shows strong earnings momentum and a bullish technical setup, making it a candidate for high-growth investors. The stock has solid revenue growth, improving margins,...
Via
Chartmill
TG THERAPEUTICS INC (NASDAQ:TGTX) - A High-Growth Stock Meeting Minervini's Trend Template
↗
July 12, 2025
TG Therapeutics (TGTX) meets Minervini's Trend Template with strong technicals and high-growth fundamentals, including 1,300% EPS growth and 90% revenue expansion. A breakout above $37.27 could signal...
Via
Chartmill
Cramer Backs This Mining Giant After $1.6B Bet
↗
July 01, 2025
Jim Cramer recommends buying Rio Tinto due to its high yield. TG Therapeutics is also a buy, with strong first-quarter sales and potential for market share growth.
Via
Benzinga
Earnings Scheduled For May 5, 2025
↗
May 05, 2025
Via
Benzinga
Why TG Therapeutics Stock Was Soaring This Week
↗
March 07, 2025
Via
The Motley Fool
TG THERAPEUTICS INC (NASDAQ:TGTX) - A High Growth Momentum Stock with Strong Technical Setup
↗
June 25, 2025
TG Therapeutics (TGTX) shows strong earnings momentum with 142% EPS growth and a bullish technical setup, making it a candidate for high-growth investors.
Via
Chartmill
TG Therapeutics Boosts Retail Sentiment With Q1 Revenue Beat Even As Stock Tumbles On Profit Miss, Conservative Outlook
↗
May 05, 2025
Investors are optimistic about the company’s prospects, particularly in the multiple sclerosis market, despite challenges from competitors.
Via
Stocktwits
TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show
↗
May 05, 2025
TG Therapeutics posts Q1 profit and nearly doubles revenue, driven by rising Briumvi sales and higher full-year guidance for 2025.
Via
Benzinga
Why TG Therapeutics Stock Was Tumbling Today
↗
May 05, 2025
Via
The Motley Fool
Crude Oil Falls Over 2%; ISM Services PMI Rises In April
↗
May 05, 2025
Via
Benzinga
TG Therapeutics Stock Tumbles After Q1 Earnings Fall Short Of Wall Street Estimates: But Retail’s Optimistic
↗
May 05, 2025
The company, however, raised its full-year 2025 global net revenue target to approximately $575 million, up from its previous guidance of $540 million.
Via
Stocktwits
Applying Mark Minervini’s growth stock checklist to TG THERAPEUTICS INC (NASDAQ:TGTX)
↗
May 02, 2025
A fundamental and technical analysis of (NASDAQ:TGTX): Is TG THERAPEUTICS INC (NASDAQ:TGTX) suited for high growth investing?
Via
Chartmill
TG Therapeutics Inc (NASDAQ:TGTX): A Strong Minervini Trend Template Candidate
↗
May 01, 2025
TG Therapeutics Inc (NASDAQ:TGTX): A Strong Minervini Trend Template Candidate
Via
Chartmill
Exploring high growth characteristics of TG THERAPEUTICS INC (NASDAQ:TGTX).
↗
April 19, 2025
UA fundamental and technical analysis of (NASDAQ:TGTX): nlocking the high Growth Potential of TG THERAPEUTICS INC (NASDAQ:TGTX).
Via
Chartmill
Price Over Earnings Overview: TG Therapeutics
↗
April 14, 2025
Via
Benzinga
Applying Mark Minervini’s growth stock checklist to TG THERAPEUTICS INC (NASDAQ:TGTX)
↗
April 05, 2025
Why TG THERAPEUTICS INC (NASDAQ:TGTX) qualifies as a high growth stock. A fundamental and technical analysis of (NASDAQ:TGTX).
Via
Chartmill
IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche
↗
April 02, 2025
The companies both have drugs that treat relapsing forms of multiple sclerosis.
Via
Investor's Business Daily
Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher
↗
March 21, 2025
TG Therapeutics has broken an important resistance level. There is a good chance that they will continue to move higher.
Via
Benzinga
How does TG THERAPEUTICS INC (NASDAQ:TGTX) stack up against Mark Minervini’s strategy?
↗
March 14, 2025
A fundamental and technical analysis of (NASDAQ:TGTX): Is TG THERAPEUTICS INC (NASDAQ:TGTX) suited for high growth investing?
Via
Chartmill
TG THERAPEUTICS INC (NASDAQ:TGTX), a growth stock which is not overvalued.
↗
March 10, 2025
Uncover the potential of TG THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:TGTX is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive...
Via
Chartmill
Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio?
↗
March 09, 2025
Top mid-cap stocks jumped up to 23.87%. Some reasons include strong gold/silver, better financial results, and market strength.
Via
Benzinga
Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains Throughout The Week
↗
March 03, 2025
Annual revenue from its MS drug, Briumvi, more than tripled, with U.S. net product revenue reaching $103.6 million in the fourth quarter and $310 million for the full year.
Via
Stocktwits
Stocks Pivot Lower On Trade Fears, Manufacturing Data
↗
March 03, 2025
Despite earlier indicating a strong start to March, stocks are lower this afternoon amid trade war concerns.
Via
Talk Markets
Topics
Stocks / Equities
World Trade
TG Therapeutics, A New Leaderboard Stock, Skyrockets 17% On Sales Beat, Bullish Guide
↗
March 03, 2025
The company has gained notoriety for its multiple sclerosis treatment.
Via
Investor's Business Daily
Topics
Earnings
Earnings Scheduled For March 3, 2025
↗
March 03, 2025
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
February 26, 2025
Via
Benzinga
8 Health Care Stocks Whale Activity In Today's Session
↗
January 20, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.